Chronic Heart Failure：企業と競争環境...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Related Reports 7
3 Market Outlook 9
3.1 Global Markets 9
3.1.1 Forecast 9
3.1.2 Drivers and Barriers – Global Issues 12
4 Current and Future Players 16
4.1 Overview 16
4.2 Trends in Corporate Strategy 17
4.3 Company Profiles 18
4.3.1 Novartis 18
5 Appendix 22
5.1 Bibliography 22
5.2 Abbreviations 22
5.3 Methodology 23
5.4 Forecasting Methodology 23
5.4.1 NYHA Class Segmentation of Total Prevalent CHF Population 23
5.4.2 Diagnosed CHF Population 24
5.4.3 Drug-Treated CHF Population 25
5.4.4 Patient Population Breakdown: HF-REF versus HF-PEF 25
5.4.5 Treatment of HF-REF versus HF-PEF 25
5.4.6 Drugs Included in Each Therapeutic Class 26
5.4.7 Launch and Patent Expiry Dates 26
5.4.8 General Pricing Assumptions 27
5.4.9 Drugs Assumptions 28
5.4.10 Generic Erosion 33
5.4.11 Pricing of Pipeline Agents 33
5.5 Physicians and Specialists Included in this Study 34
5.6 Survey of Prescribing Physicians 35
5.7 About the Authors 36
5.7.1 Author 36
5.7.2 Global Head of Healthcare 36
5.8 About GlobalData 37
5.9 Disclaimer 37